Who We Are
KELIX bio is a specialty generic business focused on Emerging Markets and designed to compete through innovation and cost leadership. KELIX bio aims to develop and commercialize affordable specialty products in jurisdictions historically deprived of access to such medications. KELIX bio’s investors include Development Partners International (“DPI”), British International Investment (“BII”), the UK’s publicly owned impact investor, and the European Bank for Reconstruction and Development (“EBRD”).
Our Shareholders
- British International Investment (BII). Learn More
- Development Partners International (DPI). Learn More
- European Bank for Reconstruction and Development (EBRD). Learn More
Our Board
Name | Role | Representation |
---|---|---|
Francesco Granata | Chairman | Kelix bio |
Florence Bachelard-Bakal | Director | European Bank for Reconstruction and Development |
Samir Abhyankar | Director | British International Investment |
Sofiane Lahmar | Director | Development Partners International |
Hocine Sidi Said | Director | Kelix bio |